Treatment-resistant depression (TRD) is one of the most persistent challenges in psychiatric practice, affecting millions of patients each year and consuming disproportionate clinical resources. The decision to escalate treatment to Transcranial Magnetic Stimulation ( TMS) or Spravato (esketamine) requires a clear understanding of TRD criteria, guideline-based timing, pros and cons of treatment options, and payer documentation requirements.
In 2026, this decision is more data-driven than ever. Clinicians who use measurement-based care, document adequacy of prior treatments, and align escalation with recognized algorithms — such as those from the VA/DoD Clinical Practice Guideline for MDD and the CANMAT 2023 update — are better positioned to secure insurance approval and improve patient outcomes.
Understanding and confirming TRD
The first step is verifying that the patient meets TRD criteria based on their specific insurance’s requirements (note that requirements may vary between insurance providers). Most leading guidelines, including the American Psychiatric Association’s practice guideline, define TRD as failure to achieve remission after at least two adequate antidepressant trials. Adequacy is a combination of dose, duration, and adherence — typically four to six weeks at a therapeutic dose, with evidence the patient actually took the medication as prescribed. Some insurances may also require failed augmentation while others may also require failed therapy.
Measurement-based care is critical here. Tools like the PHQ-9 and the MADRS provide objective benchmarks. A 50% reduction in score signals treatment response; a score below five on the PHQ-9 indicates remission. These thresholds are also reflected in the CMS depression remission quality measure, which many payers track. Regular scoring makes it much easier to justify escalation when the patient clearly isn’t improving.
The importance of timing in escalation
Tachyphylaxis, a diminishing response to subsequent medications, is commonly seen with psychiatric medications. As such, delaying escalation after multiple failed antidepressants can lead to worsening symptoms, functional decline, and chronicity. The CANMAT algorithm specifically recommends moving to interventional treatments like rTMS, TMS, or ketamine/esketamine after two failed trials, rather than exhausting every possible medication, combination, or augmentation.
For some patients — especially those with severe functional impairment, high suicide risk, or pronounced anhedonia — waiting months to explore advanced therapies is clinically risky. This is where knowing the unique advantages of TMS, Spravato, or IV Keyamine allows clinicians to select the right next step.
When TMS should be the next step
TMS is a form of non-invasive brain stimulation that delivers magnetic pulses to specific brain structures implicated in mood regulation. In general, TMS is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking cessation while some devices such as the BrainsWay, TMS device is also labeled to treat anxious depression and late-life depression.
Patients who benefit most from TMS often share one or more of these characteristics:
- Preference for a non-systemic treatment
- History of poor tolerability with medications
- Multiple comorbidities that make drug interactions risky
- Desire to avoid sedation or post-treatment downtime
- Comorbid conditions which might also respond to TMS
- Inability to get others to pick them up from treatment (a requirement for Spravato and Ketamine)
- Inability to set aside 2 or more consecutive hours 1-2 times per week (a requirement for Spravato and Ketamine)
Clinical trials, including the BrainsWay H1 coil study, have demonstrated significant improvements in depressive symptoms compared to sham treatment, with minimal systemic side effects. Based on study and device utilized, reported response and remission rates in real-world TRD cohorts can approach 80% and 65% respectively. dAdverse effects are generally limited to mild scalp discomfort or headache.
From an operational standpoint, TMS requires a series of in-office treatments — typically 36 treatments, five days a week over the course of 7-8 weeks — followed by taper or maintenance sessions as clinically indicated. This predictable schedule can be an advantage for patients who prefer structured treatment routines.
Coverage is often available through Medicare and commercial insurers, but requirements vary. Reviewing your local Medicare LCD policy or the patient’s commercial plan language is essential before initiating.
When Spravato offers the best fit
Spravato, the FDA-approved nasal spray formulation of esketamine, offers a completely different therapeutic profile. By targeting NMDA receptors, it can produce rapid antidepressant effects, sometimes within hours of the first dose. This makes it especially valuable in urgent clinical situations where traditional therapies may take weeks to act.
Patients who benefit most from Spravato often share one or more of these characteristics:
- Suicidal ideation requiring more urgent response
- Inability to come into the office on a daily basis
- Need for insurance coverage (which is not an option for IV/IM Ketamine)
- Prefer a medication-based approach
- History of implantable metal in or near the scalp (a contraindication to TMS)
- Having a chaperone available to drive them home after treatments (a REMS requirement for Spravato)
The ESCAPE-TRD trial found that Spravato plus an oral antidepressant was superior to quetiapine XR in achieving remission by week eight, with meaningful early improvement. In January 2026, FDA labeling expanded to allow Spravato as monotherapy or in combination with an oral antidepressant for TRD, while maintaining the combination requirement for its acute suicidal ideation indication. Studies have shown that response and remission rates may approach 70% and 50% respectively.
Spravato administration is subject to the REMS program, meaning it can only be dispensed in certified healthcare settings. Patients must be observed for at least two hours after dosing, with monitoring for dissociation, sedation, dizziness, blood pressure changes, and rare respiratory depression. Clinics must have the necessary equipment for continuous pulse oximetry and trained staff to respond to adverse events.
When Ketamine offers the best fit
Ketamine typically refers to the racemic mixture of Ketamine, as opposed to Spravato which is the S-enantiomer of Ketamine, or Esketamine. Ketamine is currently only FDA approved as an anaesthetic agent although many studies have supported its effect as a rapidly-acting antidepressant. It has also shown effect in other psychiatric conditions such as PTSD, OCD, and anxiety. Because Ketamine is not FDA approved for mental health conditions, it is not covered by insurance.
Patients who benefit most from Ketamine often share one or more of these characteristics:
- Don’t satisfy specific TRD criteria based on their insurance
- Able to a cover the out-of-pocket expenses
- Not specifically diagnosed with MDD (and therefore not a candidate for Spravato)
Because Ketamine is not FDA approved, there is more flexibility in dosing and indications as compared to Spravato. There are also benefits with improved and more consistent bioavailability (100% for intravenous as opposed to 50% for intranasal Spravato). However, Ketamine lacks the large-scale, multi-center, placebo-controlled studies needed for FDA approval and as a result, protocols may vary. While this offers greater flexibility in dosing, pushing boundaries with these protocols can lead to increased risks. Response rates are still considered excellent and comparable to those of Spravato.
How to choose between TMS and Spravato/Ketamine
Choosing between these advanced therapies involves weighing patient preference, clinical urgency, comorbidities, and logistical feasibility. A patient who wants a medication-free approach and can commit to daily sessions may be an ideal TMS candidate. Another who needs rapid symptom relief, has already failed TMS, or is comfortable with pharmacologic therapy might be better suited for Spravato or Ketamine.
Guidelines such as the VA/DoD MDD CPG list both TMS and Spravato/Ketamine as parallel options after failed adequate trials, allowing clinicians to tailor sequencing to individual needs.
Documentation and payer alignment
Regardless of which therapy you choose, payer approval depends on meticulous documentation. A strong prior authorization submission should include:
- Diagnosis and baseline severity score from a validated instrument
- Details of all prior adequate trials, including medications, doses, and durations
- Rationale for selecting the advanced therapy, tied directly to guideline language
- Documentation of patient consent and discussion of risks, benefits, and alternatives
Using language that mirrors payer policies — particularly for Medicare LCDs and commercial plan requirements — can reduce the risk of denial and speed up the approval process.
Integrating advanced therapies into a TRD care pathway
For optimal outcomes, TMS,Spravato, and Ketamine should be integrated into a broader care plan. Continuing evidence-based psychotherapy, maintaining regular measurement, and scheduling follow-up visits to assess progress all contribute to better long-term results. For some patients, sequencing these treatments — starting with one and switching or combining if needed — can further increase the odds of remission.
Clinics that excel in TRD care often have predefined algorithms for when to move from conventional medications to advanced therapies, including clear PHQ-9 thresholds, documentation templates for prior authorization, and patient education materials that set expectations before the first session or dose.
Key takeaway
TMS, Spravato, and Ketamine should not be considered as “last-ditch” options. They are evidence-based, guideline-endorsed treatments that can and should be considered as soon as a patient meets TRD criteria.
Acting early, with thorough documentation and payer-aligned rationale, not only improves the chance of remission but also demonstrates a commitment to delivering best-practice, measurement-driven care.